Hims & Hers Health (HIMS) Stock Price, News & Analysis

Company Overview

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California.

Key Stats

• Today's Range: $23.28 to $24.35
• 50-Day Range: $13.65 to $23.59
• 52-Week Range: $6.58 to $25.74
• Volume: 13.19 million shs
• Average Volume: 8.64 million shs
• Market Capitalization: $5.07 billion
• P/E Ratio: 53.68
• Dividend Yield: N/A
• Price Target: $21.00
• Consensus Rating: Moderate Buy

Hims & Hers Health Stock Analysis - MarketRank™

Hims & Hers Health scored higher than 74% of companies evaluated by MarketBeat, and ranked 278th out of 967 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Hims & Hers Health has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 8 buy ratings, 8 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Hims & Hers Health has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 68.18%

Earnings Growth

Earnings for Hims & Hers Health are expected to grow by 68.18% in the coming year, from $0.22 to $0.37 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Hims & Hers Health is 54.32, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 134.35.

Price to Earnings Ratio vs. Sector

The P/E ratio of Hims & Hers Health is 54.32, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 123.69.

Price to Book Value per Share Ratio

Hims & Hers Health has a P/B Ratio of 14.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

18.32% of the float of Hims & Hers Health has been sold short.

Short Interest Ratio / Days to Cover

Hims & Hers Health has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Hims & Hers Health has recently increased by 28.72%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Hims & Hers Health does not currently pay a dividend.

Dividend Growth

Hims & Hers Health does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

18.32% of the float of Hims & Hers Health has been sold short.

Short Interest Ratio / Days to Cover

Hims & Hers Health has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Hims & Hers Health has recently increased by 28.72%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.68

News Sentiment

Hims & Hers Health has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 55 news articles for Hims & Hers Health this week, compared to 13 articles on an average week.

Search Interest

71 people have searched for HIMS on MarketBeat in the last 30 days. This is an increase of 16% compared to the previous 30 days.

MarketBeat Follows

40 people have added Hims & Hers Health to their MarketBeat watchlist in the last 30 days. This is an increase of 208% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Hims & Hers Health insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,712,198.00 in company stock.

Percentage Held by Insiders

17.71% of the stock of Hims & Hers Health is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

63.52% of the stock of Hims & Hers Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

HIMS Stock Analysis - Frequently Asked Questions

How have HIMS shares performed this year?

Hims & Hers Health's stock was trading at $8.90 on January 1st, 2024. Since then, HIMS stock has increased by 168.5% and is now trading at $23.90.
View the best growth stocks for 2024 here.

How were Hims & Hers Health's earnings last quarter?

Hims & Hers Health, Inc. (NYSE:HIMS) posted its earnings results on Monday, November, 4th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.26. The company's revenue for the quarter was up 77.1% on a year-over-year basis.

Who are Hims & Hers Health's major shareholders?

Top institutional investors of Hims & Hers Health include Royce & Associates LP (0.16%), IMC Chicago LLC, Carnegie Investment Counsel (0.14%) and Principal Financial Group Inc. (0.14%). Insiders that own company stock include Melissa Baird, David B Wells, Alex Bard, Michael Chi, Patrick Harrison Carroll, Soleil Boughton, Oluyemi Okupe, Jules A Maltz, Christopher D Payne, Andrew Dudum, Christiane Pendarvis, Irene Becklund, Lynne Chou O'keefe and Jack Abraham.
View institutional ownership trends.

How do I buy shares of Hims & Hers Health?

Shares of HIMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Hims & Hers Health own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Hims & Hers Health investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Palantir Technologies (PLTR), Netflix (NFLX) and Palo Alto Networks (PANW).

Company Calendar

• Last Earnings: 11/04/2024
• Today: 11/07/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 2/24/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Offices & clinics of medical doctors
• Sub-Industry: Healthcare
• Current Symbol: NYSE:HIMS
• CUSIP: N/A
• CIK: 1773751
• Web: www.forhims.com
• Phone: 415-851-0195
• Fax: N/A
• Employees: 1,046
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $21.00
• High Stock Price Target: $28.00
• Low Stock Price Target: $10.00
• Potential Upside/Downside: -12.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 16 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.44
• Trailing P/E Ratio: 54.66
• Forward P/E Ratio: 109.32
• P/E Growth: N/A
• Net Income: $-23,550,000.00
• Net Margins: 8.19%
• Pretax Margin: 1.98%
• Return on Equity: 11.67%
• Return on Assets: 8.95%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.68
• Quick Ratio: 2.30

Sales & Book Value

• Annual Sales: $1.24 billion
• Price / Sales: 4.16
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.61 per share
• Price / Book: 14.94

Miscellaneous

• Outstanding Shares: 214,786,000
• Free Float: 176,747,000
• Market Cap: $5.17 billion
• Optionable: Optionable
• Beta: 1.06